Drug Trial Radar · NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Dec 13, 2023
Primary completion
Sep 7, 2032
Study completion Sep 7, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent central review (BICR) and (2) nemtabrutinib is superior to ibrutinib or acalabrutinib with respect to progression free survival (PFS) per iwCLL Criteria 2018 by BICR.
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
NemtabrutinibDrug
Administered orally
IbrutinibDrug
Administered orally
AcalabrutinibDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) per Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 44 months
- Progression-Free Survival (PFS) per iwCLL Criteria 2018 as assessed by BICRTime frame: Up to approximately 104 months
Locations
206 sites in 29 countries. Site status is shown where the registry gives one.
USA Mitchell Cancer Institute ( Site 0014)
Mobile, Alabama · Recruiting
Banner MD Anderson Cancer Center ( Site 0059)
Gilbert, Arizona · Recruiting
Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051)
Phoenix, Arizona · Recruiting
Arizona Oncology Associates - NAHOA ( Site 8007)
Prescott, Arizona · Completed
Alta Bates Summit Medical Center ( Site 0004)
Berkeley, California · Active not recruiting
Moores Cancer Center ( Site 0003)
La Jolla, California · Recruiting
Care Access - South Pasadena ( Site 0070)
Pasadena, California · Recruiting
Saint Joseph Hospital ( Site 0026)
Denver, Colorado · Completed
Lutheran Medical Center ( Site 0027)
Golden, Colorado · Recruiting
Intermountain Health St. Mary's Regional Hospital ( Site 0025)
Grand Junction, Colorado · Recruiting
Eastern CT Hematology & Oncology Associates ( Site 0033)
Norwich, Connecticut · Recruiting
Lynn Cancer Center at Boca Raton Regional Hospital ( Site 0063)
Boca Raton, Florida · Recruiting
Clermont Oncology Center ( Site 0046)
Clermont, Florida · Recruiting
Florida Cancer Specialists - South ( Site 7001)
Fort Myers, Florida · Recruiting
Florida Cancer Specialists - East ( Site 7002)
West Palm Beach, Florida · Recruiting
Saint Alphonsus Regional Medical Center ( Site 0067)
Boise, Idaho · Recruiting
Parkview Research Center at Parkview Regional Medical Center ( Site 0002)
Fort Wayne, Indiana · Recruiting
University of Iowa Health Care. ( Site 0017)
Iowa City, Iowa · Recruiting
University of Iowa Health Care. ( Site 0057)
Waukee, Iowa · Recruiting
Saint Elizabeth Healthcare ( Site 0041)
Edgewood, Kentucky · Recruiting
Owensboro Medical Health System ( Site 0066)
Owensboro, Kentucky · Recruiting
Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011)
Grand Rapids, Michigan · Recruiting
Regions Hospital ( Site 0042)
Saint Louis Park, Minnesota · Recruiting
MidAmerica Cancer Care, LLC ( Site 0043)
Kansas City, Missouri · Recruiting
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0052)
Billings, Montana · Recruiting
Summit Medical Group Cancer Center ( Site 0007)
Florham Park, New Jersey · Completed
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016)
Hackensack, New Jersey · Recruiting
New York Oncology Hematology, P.C. ( Site 0069)
Albany, New York · Recruiting
Roswell Park Cancer Institute ( Site 0023)
Buffalo, New York · Recruiting
RPCI Oncology, PC- Northtowns ( Site 0061)
Williamsville, New York · Recruiting
Carolina Oncology Specialists, PA ( Site 0054)
Charlotte, North Carolina · Recruiting
Southeastern Medical Oncology Center ( Site 0049)
Goldsboro, North Carolina · Recruiting
Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002)
Broomall, Pennsylvania · Recruiting
Cancer Care Associates Of York ( Site 0005)
York, Pennsylvania · Recruiting
Tennessee Oncology-Chattanooga ( Site 0045)
Chattanooga, Tennessee · Recruiting
Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031)
Nashville, Tennessee · Recruiting
Texas Oncology - Central/South Texas ( Site 8008)
Austin, Texas · Recruiting
The Center for Cancer and Blood Disorders ( Site 0032)
Fort Worth, Texas · Recruiting
Texas Oncology - San Antonio ( Site 8006)
San Antonio, Texas · Recruiting
Texas Oncology - Northeast Texas ( Site 8012)
Tyler, Texas · Recruiting
Showing 40 of 206 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.